Hedera Dx

Epalinges, Switzerland · Founded 2021 · Privately Held (backing)

Operator of a global cancer real-world data platform designed to enable molecular testing and AI-driven insights for improved cancer care outside the US. Hedera Dx is based in Epalinges, Switzerland and was founded in 2021. Its last reported valuation was $43 million in Mar 2024. It has raised $36.8 million.

Last reported valuation
$43.0M
Oct 2026
Priced at
—
Total raised
$36.8M
Last round
—
No prints on record

No secondary trades in Hedera Dx shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hedera Dx with a free account
  • ·The complete investor list: 11 names
  • ·Watch Hedera Dx: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Hedera Dx prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Hedera Dx stock.